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Abstract
Background. Minimally important differences (MIDs) allow interpretation of the clinical relevance of health-related 
quality of life (HRQOL) results. This study aimed to estimate MIDs for all European Organisation for Research and 
Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) scales for interpreting group-level 
results in brain tumor patients.
Methods. Clinical and HRQOL data from three glioma trials were used. Clinical anchors were selected for each 
EORTC QLQ-C30 scale, based on correlation (>0.30) and clinical plausibility of association. Changes in both HRQOL 
and the anchors were calculated, and for each scale and time period, patients were categorized into one of the 
three clinical change groups: deteriorated by one anchor category, no change, or improved by one anchor category. 
Mean change method and linear regression were applied to estimate MIDs for interpreting within-group change 
and between-group differences in change over time, respectively. Distribution-based methods were applied to 
generate supportive evidence.
Results. A total of 1687 patients were enrolled in the three trials. The retained anchors were performance status 
and eight Common Terminology Criteria for Adverse Events (CTCAE) scales. MIDs for interpreting within-group 
change ranged from 4 to 12 points for improvement and −4 to −14 points for deterioration. MIDs for between-group 
difference in change ranged from 4 to 9 for improvement and −4 to −16 for deterioration. Most anchor-based MIDs 
were closest to the 0.3 SD distribution-based estimates (range: 3-10).
Conclusions. MIDs for the EORTC QLQ-C30 scales generally ranged between 4 and 11 points for both within-group 
mean change and between-group mean difference in change. These results can be used to interpret QLQ-C30 re-
sults from glioma trials.
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Materials and Methods
Data Description
Data were derived from three published EORTC phase III 
trials in glioma patients. Trial 1 (EORTC 26053) evaluated 
the impact of concurrent and/or adjuvant temozolomide 
chemotherapy to radiotherapy on overall survival 
in newly diagnosed non-1p/19q deleted anaplastic 
gliomas (n  =  745).22 Trial 2 (EORTC 26951)  evalu-
ated whether adjuvant procarbazine, lomustine, 
and vincristine chemotherapy improved overall sur-
vival compared to radiotherapy alone in newly diag-
nosed patients with anaplastic oligodendrogliomas or 
anaplastic oligoastrocytomas (n = 368).23 Trial 3 (EORTC 
26981)  evaluated whether radiotherapy with concom-
itant and adjuvant temozolomide improved overall 
survival compared to radiotherapy alone in newly diag-
nosed glioblastoma patients (n  =  573).24 HRQOL was 
longitudinally assessed in all trials using the EORTC 
QLQ-C30 questionnaire. All trials were approved by the 
ethical committee of each participating center and all pa-
tients gave their informed consent to participate in the 
respective study.
EORTC QLQ-C30
The EORTC QLQ-C30 questionnaire9 contains 30 items, 
24 of which are combined into nine multi-item scales, 
ie, five functional scales (physical functioning [PF], role 
functioning [RF], cognitive functioning [CF], emotional 
functioning [EF], and social functioning [SF]) and three 
symptom scales (fatigue [FA], pain [PA], and nausea/
vomiting [NV]), and one global health status (QL) scale. 
The remaining six single-item scales assess symptoms: 
dyspnea (DY), appetite loss (AP), insomnia (SL), consti-
pation (CO), diarrhea (DI), and financial difficulties (FI). 
Trials 1 and 3 used version 3 of the EORTC QLQ-C30, 
whereas trial 2 used version 2. The two versions differ 
only in the response categories of questions 1-5 (ie, the 
PF scale), which were yes/no in version 2, whereas ver-
sion 3 uses a four-point Likert scale ranging from “not 
at all” to “very much.” The scoring of the EORTC QLQ-
C30 scales was done according to the EORTC QLQ-C30 
scoring manual,25 with the means of the raw scores for 
each scale transformed to fall between 0 and 100. To fa-
cilitate interpretation, all scales were scored such that 
0 represents the worst possible score and 100 the best 
possible score. The FI scale was omitted from the anal-
ysis because appropriate anchors were not obtainable, 
leaving 14 scales for analyses.
Clinical Anchors
Anchors for each EORTC QLQ-C30 scale were selected 
from clinical variables available in the datasets from the 
three source trials, including Common Terminology Criteria 
for Adverse Events (CTCAE), WHO PS, and MMSE, based 
on clinical plausibility and cross-sectional correlation.20 
Key Points
1.  Minimally important differences for EORTC QLQ-C30 scales ranged between 4 and 
11 points in glioma.
2.  Estimate for each HRQOL scale can be used to better interpret group-level results 
in glioma trials.
Despite multimodal anti-cancer treatment, patients with pri-
mary and metastatic brain cancer have a poor prognosis. The 
most common malignant primary brain tumors are gliomas, 
with median survival rates ranging between 15 months and 
>15 years, depending on the histological tumor type, ma-
lignancy grade, and tumor genetics.1 For these patients, the 
quality of survival is of utmost importance.
Health-related quality of life (HRQOL) is typically included 
as a secondary outcome in brain tumor clinical trials,2–8 as 
a key component of determining the net clinical benefit of 
a treatment strategy. This means that the benefits of pos-
sible prolonged survival are weighed against the possible 
negative effects of treatment on the patients’ level of func-
tioning and well-being. The most common instruments 
used in brain tumor clinical trials to evaluate HRQOL are 
the European Organisation for Research and Treatment of 
Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-
C30),9 Functional Assessment of Cancer Therapy—General 
(FACT-G),10 and the MD Anderson Symptom Inventory,11 
typically combined with their brain-specific modules.12–14
The impact of an experimental treatment on HRQOL is 
usually evaluated by comparing mean HRQOL scores over 
time in the experimental vs the control arm. Some studies 
rely on statistical significance alone to assess differences 
between treatment arms.3,15 However, to demonstrate a 
true impact, differences should be both statistically signifi-
cant and clinically relevant. For some questionnaires, mini-
mally important differences (MIDs) have been determined, 
allowing to interpret differences and changes in HRQOL as 
clinically meaningful. Indeed, an MID can be considered 
as the smallest change/difference in a HRQOL score that 
is perceived as relevant or important by the patient and 
would indicate a change in the patient’s disease manage-
ment. Historically, for the EORTC QLQ-C30 questionnaire, 
a crude MID between 5 and 10 points was suggested to 
represent a small difference, between 10 and 20 points a 
moderate difference, and >20 a large difference, for both 
mean changes over time16 and for mean differences be-
tween groups.17 Therefore, in earlier studies, a difference of 
>10 points was considered clinically relevant for all scales. 
More recent work, however, suggests that these MIDs are 
too simplistic18,19; they do not distinguish between domain 
scales, direction of change (ie, improvement or deteriora-
tion), and disease sites. Therefore, MIDs for each EORTC 
QLQ-C30 scale specifically for glioma patients are needed, 
as they will be helpful in evaluating whether observed dif-
ferences in HRQOL scores over time between treatment 
arms in a clinical trial are also clinically meaningful.
There are two approaches to estimating MIDs. The 
anchor-based approach links HRQOL measures to external 
criteria, either a factor that has clinical relevance (eg, per-
formance status [PS]) or patient- or physician-reported 
ratings of health (eg, adverse events). The distribution-
based approach, on the other hand, relies on the statistical 
features of HRQOL data (eg, standard deviation [SD]), and 
is typically used as supportive evidence for anchor-based 
estimates.20 Maringwa et al. previously published MIDs for 
brain tumor patients based on two anchors, PS and Mini-
Mental State Examination (MMSE) scores.21 However, 
these anchors were suitable for only seven selected 
HRQOL scales. MID estimates for the selected scales, de-
rived for both improvement and deterioration, were found 
to range between 5 and 14 points,21 providing further evi-
dence that the 10-point threshold is overly simplistic.
The aim of this study was to estimate the MIDs for all 
EORTC QLQ-C30 scales for interpreting group-level 
changes over time within a group of glioma patients, and 
for interpreting the mean difference in change between 
two groups, using both anchor-based and distribution-
based approaches.
Importance of the Study
Minimally important differences (MIDs) allow interpre-
tation of the clinical relevance of health-related quality 
of life (HRQOL) results. Typically, a score of >10 points 
was considered clinically relevant for all scales. More 
recent work, however, suggests that these MIDs are too 
simplistic as they do not distinguish between domain 
scales, direction of change (ie, improvement or deteri-
oration), and disease sites. In this study, we estimated 
MIDs for all EORTC QLQ-C30 scales for interpreting 
group-level changes over time within a group of glioma 
patients, and for interpreting the mean difference in 
change between two groups, using both anchor-based 
and distribution-based approaches. We found that 
MIDs for the EORTC QLQ-C30 scales generally ranged 
between 4 and 11 points for both within-group mean 
change and between-group mean difference in change, 
representing small changes. The current estimates can 
be used to better interpret the results of clinical trials in 
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Data were derived from three published EORTC phase III 
trials in glioma patients. Trial 1 (EORTC 26053) evaluated 
the impact of concurrent and/or adjuvant temozolomide 
chemotherapy to radiotherapy on overall survival 
in newly diagnosed non-1p/19q deleted anaplastic 
gliomas (n  =  745).22 Trial 2 (EORTC 26951)  evalu-
ated whether adjuvant procarbazine, lomustine, 
and vincristine chemotherapy improved overall sur-
vival compared to radiotherapy alone in newly diag-
nosed patients with anaplastic oligodendrogliomas or 
anaplastic oligoastrocytomas (n = 368).23 Trial 3 (EORTC 
26981)  evaluated whether radiotherapy with concom-
itant and adjuvant temozolomide improved overall 
survival compared to radiotherapy alone in newly diag-
nosed glioblastoma patients (n  =  573).24 HRQOL was 
longitudinally assessed in all trials using the EORTC 
QLQ-C30 questionnaire. All trials were approved by the 
ethical committee of each participating center and all pa-
tients gave their informed consent to participate in the 
respective study.
EORTC QLQ-C30
The EORTC QLQ-C30 questionnaire9 contains 30 items, 
24 of which are combined into nine multi-item scales, 
ie, five functional scales (physical functioning [PF], role 
functioning [RF], cognitive functioning [CF], emotional 
functioning [EF], and social functioning [SF]) and three 
symptom scales (fatigue [FA], pain [PA], and nausea/
vomiting [NV]), and one global health status (QL) scale. 
The remaining six single-item scales assess symptoms: 
dyspnea (DY), appetite loss (AP), insomnia (SL), consti-
pation (CO), diarrhea (DI), and financial difficulties (FI). 
Trials 1 and 3 used version 3 of the EORTC QLQ-C30, 
whereas trial 2 used version 2. The two versions differ 
only in the response categories of questions 1-5 (ie, the 
PF scale), which were yes/no in version 2, whereas ver-
sion 3 uses a four-point Likert scale ranging from “not 
at all” to “very much.” The scoring of the EORTC QLQ-
C30 scales was done according to the EORTC QLQ-C30 
scoring manual,25 with the means of the raw scores for 
each scale transformed to fall between 0 and 100. To fa-
cilitate interpretation, all scales were scored such that 
0 represents the worst possible score and 100 the best 
possible score. The FI scale was omitted from the anal-
ysis because appropriate anchors were not obtainable, 
leaving 14 scales for analyses.
Clinical Anchors
Anchors for each EORTC QLQ-C30 scale were selected 
from clinical variables available in the datasets from the 
three source trials, including Common Terminology Criteria 
for Adverse Events (CTCAE), WHO PS, and MMSE, based 
on clinical plausibility and cross-sectional correlation.20 
First, we assessed correlation. Depending on the distribu-
tion of the HRQOL scale/anchor pair, either a polyserial or 
polychoric correlation was estimated. Anchors with correl-
ations of ≥|0.30|26 were prioritized and where achievable, 
anchors with much stronger correlations were targeted.27 
The retained anchors were then assessed by a panel of 
five experts in both brain cancer and HRQoL for clinical 
plausibility.28
Definition of Clinical Change Groups
For each scale and time period, patients were categorized 
into one of the three clinical change groups: (i) deterio-
ration (worsened by one anchor category), (ii) stable (no 
change in anchor categories), and (iii) improvement (im-
proved by one anchor category). Patients who changed by 
≥2 categories of an anchor were excluded because they 




The data were pooled across all three trials. Next, change 
scores for each EORTC QLQ-C30 scale and anchor pair were 
computed across all available pairwise time points during 
the entire follow-up period, and then combined into one 
dataset to provide sufficient data for examining clinically 
relevant changes. As an example, for a patient measured 
at time points ta, tb, and tc, change scores were computed 
between ta & tb, ta & tc, and tb & tc. This meant that one pa-
tient could contribute to multiple change scores, and given 
their change scores, patients could contribute to multiple 
clinical change groups.
The mean change method was used to estimate MIDs for 
interpreting change over time within a group of patients. 
MIDs for improvement and deterioration corresponded 
to the mean HRQOL change scores within the improve-
ment and deterioration clinical change groups, respec-
tively. Moreover, for a given HRQOL scale, an effect size 
(ES) was computed within each clinical change group by 
dividing the mean of the HRQOL change scores (derived 
from all the pairwise time point differences) by the SD of 
the HRQOL change scores over all time points. Cohen29 re-
commended that an ES of 0.2 is small, 0.5 is moderate, and 
≥0.8 is large. Based on this guideline, only mean changes 
with an ES ≥0.2 and <0.8 were considered appropriate for 
inclusion as MIDs. The rationale was that an observed ES 
<0.2 reflects changes that are clinically unimportant, while 
ESs ≥0.8 were considered to reflect changes more than 
minimally important.
A linear regression approach was used to estimate 
MIDs for interpreting differences in change score over 
time between two distinct groups of patients. For a given 
EORTC QLQ-C30 scale, the outcome variable was the scale 
change score, and the covariate was a binary anchor vari-
able with categories “stable”  =  0 and “improvement”  =  1 
when modeling improvement (deteriorated observations 
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deterioration. Since some patients contributed change 
scores to multiple clinical change groups, and more than 
one change score to a particular clinical change group, we 
corrected for the association between multiple change 
scores contributed by these patients by specifying a suitable 
covariance structure using generalized estimating equa-
tions (GEE).30 The MIDs for improvement and deterioration 
correspond to the slope parameters for the “improved” and 
“deteriorated” covariates, respectively, and are useful for 
interpreting differences in change scores between groups 
of patients. Multiple MID values for a given scale were sum-
marized to single values via correlation-based weighted av-
erage. To check whether using data from different trials had 
an impact on the estimated MIDs, this trial effect (ie, interac-
tion between the trial and the anchor indicator) was included 
as covariate in the regression models. To account for mul-
tiple testing across the EORTC QLQ-C30 scales, we chose a 
priori to apply more stringent P values, ie, P values below 
.001 were considered statistically significant.
Distribution-based method
Two distribution-based methods were used, with calcu-
lations for each QLQ-C30 scale based on cross-sectional 
analysis; ie, the time point before or on the first day of treat-
ment administration (t1). Three proportions of an SD (0.2 SD, 
0.3 SD, 0.5 SD) were calculated, representing the range of 
proportions currently considered relevant to MID estima-
tion,18,31,32 although there is no consensus on which best 
approximates the MID. The standard error of measurement 
(SEM) was calculated as SD multiplied by square root of 
(1–r), using SD at t1. The test-retest reliability estimates (r) for 
the QLQ-C30 scales were obtained from Hjermstad et al.33
All statistical analyses were performed using SAS ver-
sion 9.4.34 In addition, two practical examples are provided 
to explain how MID results can be used to interpret HRQOL 
data from clinical trials and how MIDs can be used for a 
sample size calculation for a clinical trial in which HRQOL is 
the primary endpoint.
Results
A total of 1687 patients were enrolled across the three 
trials. Baseline characteristics are summarized in Table 1. 
Supplementary Figure S1 presents an overview of patient 
inclusion for the anchor-based method.
Anchor-Based Method
The final list of retained anchors, summarized in Table 2, 
comprised PS, scored between 0 (no symptoms of cancer) 
and 4 (bedbound), and eight CTCAEs (pain, fatigue, nausea 
and vomiting, gastrointestinal, constipation, anorexia, 
dyspnea, and neurology), which are graded between 0 (no 
toxicity) and 4 (life-threatening). At least one clinical an-
chor could be retained for 12/14 EORTC QLQ-C30 scales 
assessed, with insomnia and diarrhea therefore being ex-
cluded from further analysis.
  
Table 1 Baseline Patient Sociodemographic and Clinical Characteristics for Each Trial Separately and for the Total Population
Trial Total  
(N = 1697)26053 (N = 756) 26951 (N = 368) 26981 (N = 573)
 N (%) N (%) N (%) N (%)
Gender     
 Male 448 (59.3) 212 (57.6) 360 (62.8) 1020 (60.1)
 Female 308 (40.7) 156 (42.4) 213 (37.2) 677 (39.9)
WHO performance status     
 0 440 (58.2) 138 (37.5) 223 (38.9) 801 (47.2)
 1 284 (37.6) 172 (46.7) 277 (48.3) 733 (43.2)
 2 32 (4.2) 58 (15.8) 73 (12.7) 163 (9.6)
Region     
 Northern Europe 0 (0.0) 15 (4.1) 1 (0.2) 16 (0.9)
 Southern Europe 64 (8.4) 43 (11.7) 57 (9.9) 164 (9.7)
 Western Europe 482 (63.8) 300 (38.3) 324 (56.5) 1106 (65.2)
 Eastern Europe 0 (0.0) 10 (2.7) 6 (1.0) 16 (0.9)
 Non-European 210 (27.8) 0 (0.0) 185 (32.3) 395 (23.3)
Age     
 Mean (SD) 43.01 (13.17) 47.62 (11.11) 53.81 (10.39) 47.65 (12.76)
 Interquartile 32.0-52.0 40.0-55.0 48.0-62.0 37.0-58.0
Northern Europe: Sweden, Finland; Southern Europe: Italy, Spain; Western Europe: the Netherlands, France, United Kingdom, Germany, Belgium, 
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The cross-sectional correlations between the different 
HRQOL scales and anchors ranged from 0.30 to 0.55 in abso-
lute value, and the correlations between their change scores 
ranged from 0.20 to 0.40 (Table 2). Supplementary Table 
S1 provides the distribution of patients and the number of 
change observations across change categories of the var-
ious anchors. According to the anchor change scores, most 
patients were stable on all anchors. The number of patients 
who either improved or deteriorated was similar for most 
anchors except for PS, in which more patients deteriorated 
than improved. Anchor-based MIDs with clinically important 
ES could be determined for deterioration in 12 EORTC QLQ-
C30 scales assessed, and in 11 scales for improvement. The 
anchor-based MIDs for change within-group and between-
group differences in change over time are presented in Table 
3. Supplementary Table S2 reports full details for both the 
mean change method (within-group change) and the linear 
regression method (between-group difference in change). 
Note that only MIDs estimated from anchor clinical change 
groups with a clinically important ES ≥0.2 and <0.8 contrib-
uted to MID estimates in Table 3.
Figure 1 presents MIDs from the mean change method 
(see also Table 3), plotted alongside their 95% confidence 
intervals, showing how MIDs vary by EORTC QLQ-C30 
scale, direction of change (improvement vs deterioration), 
and anchor. All MID estimates were always in the expected 
direction, ie, positive vs negative mean change scores 
within the improvement vs deterioration clinical change 
group respectively. MIDs for interpreting within-group 
change (derived from the mean change method) ranged 
from 4 to 12 points for improvement and −14 to −4 points 
for deterioration. MIDs for between-group difference in 
change (derived from the linear regression) ranged from 4 
to 9 for improvement and −16 to −4 deterioration (Table 3).
Taking into account the weighted summaries, MIDs for 
the EORTC QLQ-C30 scales generally ranged from 4 to 
11 points in absolute values for both within-group and 
between-group changes. Adding the trial effect to the re-
gression models showed no statistically significant dif-
ferences for improving or deteriorating scores (data not 
shown), supporting the combination of the three trials.
Distribution-Based Method
Distribution-based estimates for all 14 EORTC QLQ-
C30 scales considered in our analyses are presented in 
Supplementary Table S3. Most anchor-based MIDs were 
closest to the distribution-based estimates when using 0.3 
SD as cutoff, ranging between 3.40 and 9.86.
Practical Examples
Table 4 presents two practical example examples on how 
MIDs can be used to interpret HRQOL results in a glioma 
clinical trial (example 1), or to calculate the sample size for 
  
Table 2 Cross-Sectional Correlations of the EORTC QLQ-C30 Scales With Anchors and Correlations Between Their Change Scores
 Cross-Sectional Change Scores
Scale Anchor N (No) Correlation N (No) Correlation
Physical functioning Performance status 1317 (9687) −0.52 921 (66765) −0.31
Role functioning Performance status 1325 (9655) −0.51 921 (66551) −0.24
Social functioning Performance status 1330 (9660) −0.41 921 (66209) −0.20
Emotional functioning Performance status 1326 (9669) −0.30 921 (66288) −0.20
Cognitive functioning Performance status 1331 (9682) −0.39 921 (66315) −0.20
Cognitive functioning CTCAE neurological 653 (3803) −0.30 548 (18407) −0.20
Global health status Performance status 1330 (9653) −0.43 921 (66045) −0.20
Global health status CTCAE fatigue 1179 (5577) −0.33 975 (21129) −0.20
Pain CTCAE pain 654 (4015) −0.44 548 (18570) −0.30
Fatigue Performance status 1334 (9701) −0.44 975 (66662) −0.30
Fatigue CTCAE fatigue 1178 (5616) −0.43 975 (21393) −0.30
Nausea and vomiting CTCAE nausea vomiting 1182 (5630) −0.55 975 (21431) −0.38
Nausea and vomiting CTCAE gastrointestinal 1182 (5630) −0.42 677 (21431) −0.30
Appetite loss CTCAE nausea vomiting 1182 (5616) −0.33 975 (21359) −0.20
Appetite loss CTCAE gastrointestinal 1182 (5616) −0.36 677 (21359) −0.22
Appetite loss CTCAE anorexia 1181 (5614) −0.52 975 (21355) −0.33
Dyspnea CTCAE dyspnea 654 (3812) −0.44 548 (18511) −0.21
Constipation CTCAE gastrointestinal 1179 (5597) −0.30 677 (21232) −0.20
Constipation CTCAE constipation 526 (1795) −0.53 427 (2800) −0.40
Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events; EORTC QLQ-C30, European Organisation for Research and Treatment of 
Cancer Quality of Life Questionnaire Core 30.
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a clinical trial in glioma patients in which HRQOL is the pri-
mary endpoint (example 2).
Discussion
The MIDs for most scales of the EORTC QLQ-C30 estimated 
in this study can be used to interpret group-level changes 
over time in glioma patients. MIDs generally ranged from 
4 to 11 points, both for change within-group and between-
group differences in change. Moreover, the magnitude of 
the MIDs per scale was fairly similar for both deterioration 
and improvement.
The results of this study underline the assumption that 
using one MID as clinically relevant for all EORTC QLQ-C30 
scales in all cancers is too simplistic. Although the MIDs for 
the direction of change were fairly similar for each scale, 
there was a wide range in MIDs between the different 
scales in this brain tumor population. For only a minority 
of scales, the MID was >10 points,16 meaning that applying 
this cutoff may possibly have resulted in an underestima-
tion of clinically relevant differences between and within 
groups in previously analyzed brain cancer trials. Our re-
sults also highlight that MIDs differ across disease sites. 
For example, QLQ-C30 MIDs for (advanced) cancer patients 
were not equal to those of glioma patients.26,35,36
It should be emphasized that the presented MIDs are 
developed for interpreting group-level results of analyses 
based on HRQOL scales as continuous variables. They may 
not be applicable to analyses of HRQOL-derived metrics at 
the individual patient level (ie, responder analyses), eg, re-
porting the proportion of patients that changed in HRQOL 
by a clinically important degree in a specific time period 
or the time to HRQOL deterioration. A project to establish 
so-called responder thresholds for changes in HRQOL on 
the individual patient level is currently ongoing.28
Previously, Maringwa et  al.21 estimated MIDs for five 
scales of the EORTC QLQ-C30 and two scales of the brain 
cancer-specific EORTC QLQ-BN20 using two trials that 
are also used in this study. They found MIDs ranging be-
tween 5 and 14 points. For the scales that could be com-
pared between studies, the MIDs found by Maringwa et al. 
were generally a few points higher than those found in our 
study. Differences may be explained by the number and 
type of anchors that were used, as well as methodological 
differences, ie, number of time points to calculate changes 
and number of patients within each clinical change group. 
In contrast to the study of Maringwa et  al., the current 
study included all scales of the EORTC QLQ-C30, except 
for financial difficulties, insomnia or diarrhea for which no 
anchor was available or could be established, and MIDs 
for both change within-group and between-group dif-
ferences in change were calculated. In the current study, 
brain tumor-specific functioning and symptoms as meas-
ured with the EORTC QLQ-BN20 were not included, while 
these may be particularly relevant for brain tumor patients. 
Currently, the EORTC QLQ-BN20 is undergoing a revi-
sion, as this questionnaire has been developed in 199612 
with an international validation in 2010,13 and treatments 
have changed since then. These new treatments bring new 
toxicities, eg, eye problems,37 which are not sufficiently 
covered by the current version. For the revised brain 
cancer module, it would also be important to determine 
scale-specific MIDs that can be used to interpret differ-
ences or changes in HRQOL scores in brain cancer clinical 
trials. It should be noted though, that the clinical trial data 
that were used in this study was based on glioma patients 
only. The MIDs derived in this study may therefore not be 
applicable to all brain cancer populations, including those 
  
Table 3 Summary of Anchor-Based MIDs (Weighted Average) for Within-Group and Between-Group Difference in Change Over Time
Within-Group Changea Between-Group Difference in Changea
Scale Improvement Deterioration Improvement Deterioration
Physical functioning 5 −9 5 −7
Role functioning 9 −9 8 −9
Social functioning 6 −6 5 −6
Emotional functioning 6 −5 4 −4
Cognitive functioning No MID −9 to −5 (−7) No MID −6.1 to −5.0 (−5.5)
Global health status 4 to 6 (5)b −6 3.6 to 5.3 (4.4) −6
Fatigue 8.2 to 9.2 (8.7)b −8 to −6 (−7) 7.5 to 7.7 (7.6) −8 to −7 (−7.4)
Pain 6 −8 7 −6
Nausea and vomiting 7 −7 6.42 −7
Dyspnea 9 −8 6.64 −8
Appetite loss 10.9 to 11.7 (11.3)b −5.3 to −4.3 (−4.8) 9.21 to 9.24 (9.22) −7.6 to −7.4 (−7.5)
Constipation 5 −14 to −9 (−10) 5 −16 to −7 (−10)
Abbreviation: MIDs, minimally important differences.
aThe within-group MIDs are derived from the mean change method and the between-group MIDs from the linear regression.
bThe numbers between brackets represent the weighted correlations, and only applies to scales with more than one anchor retained.
Note: The symptom scores were reversed to follow the functioning scales’ interpretation, ie, 0 represents the worst possible score and 100, the best 
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with metastatic brain cancer, in which the EORTC QLQ-C30 
is often used. Also, the EORTC questionnaires are regu-
larly used in studies including patients with benign brain 
tumors, such as meningioma.38–40 Whether these MIDs 
are also applicable to other types of brain tumors there-
fore remains to be determined. Another limitation in clin-
ical trials that may have impacted the estimations of the 
MIDs is missing HRQOL data. In all three trials, compliance 
rates with HRQOL assessment decreased over time, which 
is likely related to the health status of the patient. Patients 
with a better health status may have been overrepresented 
during follow-up, hampering generalizability of our results.
Although the correlations between the HRQOL scales 
and anchors were not strong, ie, between 0.2 and 0.4 for 
the change scores, estimates from the distribution-based 
method using the 0.3 SD cutoff were comparable to those 
derived with the anchor-based method. Currently, there is no 
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Fig. 1 Mean change and 95% confidence interval for improvement and deterioration in EORTC QLQ-C30 scales, across multiple anchors. 
Estimates are available only for scales with at least 1 suitable anchor and with effect size >=0.2 and <0.8. These mean change scores are useful 
for interpreting within-group change over time. Abbreviation:  AP, appetite loss; CO, constipation; CF, cognitive functioning; CTCAE, common termi-
nology criteria for adverse events; DY, dyspnea; EF, emotional functioning; FA, fatigue; NV, nausea/vomiting; PA, pain; PF, physical functioning, QL, 
global health status; RF, role functioning; SF, social functioning. Deteriorate = worsened by at least 1 anchor category; no change = no change in 
anchor categories; improve = improved by at least 1 category.
  
  
Table 4 Practical Examples on How Minimally Important Differences (MIDs) Can Be Used to (1) Interpret Health-Related Quality of Life (HRQOL) 
Results in a Glioma Clinical Trial or (2) to Calculate the Sample Size for a Clinical Trial in Glioma Patients in Which HRQOL Is the Primary Endpoint
Practical example 1
In this example, we will illustrate how the MIDs can be used to interpret HRQOL results in a clinical trial. In a clinical trial comparing 
treatment A with treatment B, a statistically significant mean difference in change of 3 points between the two treatment arms was 
found for the physical functioning scale (both arms deteriorated in their level of physical functioning, treatment A with 2 points and 
treatment B with 5 points). The estimated MID for deterioration of physical functioning was found to be 7 points (Table 3). This means 
that although the observed difference of 3 points between treatment arms was statistically significant, this difference cannot be con-
sidered clinically meaningful and would not require a change in patient management. In this case, we should conclude that the treat-
ments were similar in their impact on the patients’ HRQOL. Such a scenario is quite plausible in a trial with a large sample size, where 
HRQOL comparisons will be statistically overpowered.
Practical example 2
Another application of the estimated MIDs is their use in the sample size calculation for a clinical trial in glioma patients in which HRQOL 
is the primary endpoint. For example, it is expected that the deterioration in physical functioning with treatment A will be less pro-
nounced than the deterioration in physical functioning with treatment B. The difference in deterioration between the treatment arms is 
expected to be clinically meaningful. In that case, we could use the MID for deterioration, which is 7 points, as the mean difference that is 
needed to detect a clinically meaningful difference between the treatment arms, and power/calculate the sample size accordingly. 
  
  
Table 3 Summary of Anchor-Based MIDs (Weighted Average) for Within-Group and Between-Group Difference in Change Over Time
Within-Group Changea Between-Group Difference in Changea
Scale Improvement Deterioration Improvement Deterioration
Physical functioning 5 −9 5 −7
Role functioning 9 −9 8 −9
Social functioning 6 −6 5 −6
Emotional functioning 6 −5 4 −4
Cognitive functioning No MID −9 to −5 (−7) No MID −6.1 to −5.0 (−5.5)
Global health status 4 to 6 (5)b −6 3.6 to 5.3 (4.4) −6
Fatigue 8.2 to 9.2 (8.7)b −8 to −6 (−7) 7.5 to 7.7 (7.6) −8 to −7 (−7.4)
Pain 6 −8 7 −6
Nausea and vomiting 7 −7 6.42 −7
Dyspnea 9 −8 6.64 −8
Appetite loss 10.9 to 11.7 (11.3)b −5.3 to −4.3 (−4.8) 9.21 to 9.24 (9.22) −7.6 to −7.4 (−7.5)
Constipation 5 −14 to −9 (−10) 5 −16 to −7 (−10)
Abbreviation: MIDs, minimally important differences.
aThe within-group MIDs are derived from the mean change method and the between-group MIDs from the linear regression.
bThe numbers between brackets represent the weighted correlations, and only applies to scales with more than one anchor retained.
Note: The symptom scores were reversed to follow the functioning scales’ interpretation, ie, 0 represents the worst possible score and 100, the best 
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but 0.2 SD has previously been suggested to reflect a clini-
cally important small effect,29 and 0.3 SD has been suggested 
to reflect an appropriate threshold for defining MIDs.41 Also, 
the estimated MIDs were often within a relatively small 
range and in the expected direction of change similar to the 
anchor, and the final MID estimates were based on correla-
tion weighted averages thereby mitigating the influence of 
weaker anchors, further supporting the use of the chosen an-
chors. Moreover, the anchors that were retained based on 
statistical considerations were subsequently reviewed by 
experts on their clinical plausibility to avoid spurious find-
ings. However, not all (clinically) appropriate anchors may 
have been available to determine MIDs, since we used ex-
isting data of closed clinical trials. For example, we were not 
able to establish an MID for improvements in the cognitive 
functioning scale, while this is an important outcome for 
brain tumor patients, as over 80% of patients with primary 
or metastatic brain cancer have neurocognitive impairments 
at diagnosis.42–44 In this study, PS and CTCAE neurological 
were used as clinical anchors for cognitive functioning, but 
change scores in cognitive functioning had weak correl-
ations with change in the respective anchors, both −0.20. 
This may be due to the fact that both anchors were physician-
reported, which are subjective by nature. Although objec-
tive neurocognitive functioning is often measured in brain 
tumor trials, the correlation between objectively meas-
ured neurocognitive functioning and cognitive complaints 
as measured with a patient-reported outcome is generally 
poor.45–47 This was also true for this study; MMSE was con-
sidered as a clinical anchor as this outcome was measured 
in all trials, but the correlations were <0.30 and therefore 
excluded from further analyses. Using a patient-reported 
outcome to assess cognitive complaints, eg, MOS (Medical 
Outcomes Study) Cognitive Functioning Scale,48 may have 
been a more appropriate anchor. Otherwise, more objective 
anchors should be identified and used in clinical trials.
In conclusion, our study provides estimates for MIDs 
for group-level interpretation of the EORTC QLQ-C30 in 
glioma patients. In general, the estimates range between 
4 and 11 points and correspond to small differences as pro-
posed by Cocks et al. in the guidelines for interpretation 
of longitudinal HRQOL differences.18 The current estimates 
can be used to better interpret results of clinical trials in 
glioma patients, and subsequently inform patients, as well 
as for sample size calculations for planning future glioma 
clinical trials. Advances to establish MIDs to evaluate 
changes in HRQOL on the individual patient level, which is 
relevant in clinical practice, are currently ongoing.49
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